Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2014/09/005002
CTRI/2014/09/005002
Recruiting
未知

nderstanding the genetic basis of chemotherapy resistance in gingivobuccal squamous cell carcinoma (GSCC)

DBT0 sites12 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
DBT
Enrollment
12
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
DBT

Eligibility Criteria

Inclusion Criteria

  • •1\.Previously untreated borderline resectable GB SCC i.e T4a lesions
  • •2\.Histological proven diagnosis of squamous cell cancer
  • •3\.Signed informed consent
  • •4\.Adequate organ function
  • •Hematological\- Hb \> 9 g/dL, ANC \>\= 1\.5 x 109/L, platelets \>\= 100 x 109/L.
  • •Liver functions\- bilirubin\<\= 2x upper limit normal (ULN), S. albumin\>\=30 g/L.
  • •Renal function\- Creatinine \<\= 2 ULN, Creatinine clearance \> 30 mL/min.
  • •Performance score (KPS) \> 80 or ECOG \<\= 2

Exclusion Criteria

  • •1\.Distant metastasis present
  • •2\.Serious co\-morbidities such as severe cardiac failure or severe pulmonary compromise or severe and active infections.
  • •3\.Patients not suitable for any chemotherapy.
  • •4\.Patient is currently enrolled in a clinical trial for another investigational therapy.
  • •5\.Pregnancy
  • •6\.Patients in whom chemotherapy is advised for a palliative intent will not be considered for the study because chemotherapy will be very varied and may be metronomic in nature which will cause wide differences in the final analysis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"Carcinoma, Non-Small-Cell Lung
NCT00222404University Hospital, Grenoble556
Active, not recruiting
Not Applicable
Pharmacogenomics in optimizing the chemotherapy in the treatment of colorectal carcinoma - AOBS-FOBERL-COBIOMARCOLORECTAL NEOPLASTIC DISEASEMedDRA version: 9.1Level: LLTClassification code 10009973MedDRA version: 9.1Level: LLTClassification code 10009974
EUCTR2010-019805-41-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
Completed
Not Applicable
Molecular genetic elucidation of pharmacokinetics of propofolRelationship between propofol and genes
JPRN-UMIN000027630Department of Anesthesiology and Perioperative Medicine, Tohoku University School of Medicine100
Unknown
Phase 2
First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by SurgeryLung Cancer
NCT00736814Yonsei University117
Active, not recruiting
Phase 1
The BARCODE 2 Study – The Use of Genetic Profiling to Guide Prostate Cancer TreatmentProstate CancerMedDRA version: 19.0Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000869-23-GBThe Institute of Cancer Research